Naringin and its aglycone naringenin, widely distributed in traditional Chinese medicines, had received extensive studies on their bioactivities. However, the plasma protein binding ratio, which played a very important role on pharmacokinetic and pharmacodynamic studies, remained unclear. In this present study, the protein binding of naringin and naringenin in rat, dog and human plasma was investigated using equilibrium dialysis and a liquid chromatography with electrospray ionization tandem mass/mass spectrometry (LC-ESI-MS/MS). The analytical time was less than 5 min without sacrificing resolution using ZORBAX Eclipse Plus-C18 (2.1 × 100 mm, 1.8 μm) column and MS/MS mode performed for multiple reaction monitoring. The plasma protein binding ratios of naringin were 83.30 to 84.56%, 72.14 to 74.06% and 48.17 to 51.33% in rat, human and dog plasma, respectively. No obvious concentration dependence was observed across the entire concentration range. On the other hand, the binding ratios for aglycone naringenin in three species plasma exceed 94% over all concentration studied, which suggested that naringenin existed predominantly in the bound form in the circulation blood at a wide range of naringenin concentration. The results may be speculated and make further impacts on their pharmacokinetic study.
INTRODUCTION
Plasma protein binding plays a very important role on the pharmacokinetic and pharmacodynamic studies of chemical entities. It is widely accepted that the protein-bound drug is a lager complex that could not easily transfer cell membrane. The unbound fraction is the major contributor to affecting the absorption, distribution, metabolism and excretion of a chemical in the body, thus influence its effect intensity and time (Weiss et al., 2008; Tesseromatis and Alevizou, 2008) . Therefore clear understanding of the unbound fraction is essential for drug development and safety evaluation.
Naringin and naringenin, widely distributed in the traditional Chinese medicines (Li et al., 2004; Guo et al., 2011; Tong et al., 2012) , has been studied extensively for their diverse biological activities. Naringin was reported to possess anti-inflammatory (Jain and Parmar, 2011 anti-oxidant (Golechha et al., 2011) , anti-osteoporotic (Wei et al., 2007) , anti-atherogenic (Lee et al., 2001 ) and anti-tussive (Gao et al., 2011) effects. Naringenin, the aglycone of naringin, was found to potently inhibit lipopolysaccharide-induced inflammatory status (Chao et al., 2010) , and decrease atherosclerosis (Mulvihill et al., 2010) as well as exhibiting anti-oxidant (Cavia-Saiz et al., 2010) , anti-sindbis (Paredes et al., 2003) , anti-ulcer (Parmar, 1983) and mucoregulator activities . All these given reflect a good prospect for naringin and naringenin to develop into new drugs.
Up till now, the pharmacokinetics of oral naringin have been investigated in rat (Fang et al., 2006) , rabbit (Hsiu et al., 2002) and dog (Mata-Bilbao et al., 2007) . The pharmacokinetics of naringenin, the aglycone of naringin, was studied in rats (Yanez et al., 2008; Wan et al., 2011) , rabbit (Hsiu et al., 2002) and human (Gardana et al., 2007; Kanaze et al., 2007) . Furthermore, the pharmacokinetic parameters exhibited species differences in their dispositions. Though some basic information for understanding bioavailability and bioefficacy is thus accessible, there was no data of plasma protein binding reported yet. The pharmacological activity of a compound depends on its pharmacokinetics as well as pharmacodynamic properties and plasma protein binding might affect both (Schmidt et al., 2010) . Thus, knowledge about the protein binding of naringin and naringenin is beneficial for understanding the transport and metabolic process in different species and provide a deep insight into their pharmacodynamic research.
In early studies, we have reported a simple, sensitive, and wide linear range method to determine both of them in rat and dog plasma by LC-ESI-MS/MS (Liu et al., 2011; . But the method of simultaneous determination of naringin and naringenin in human plasma by liquid chromatography with electrospray ionization tandem mass/mass spectrometry (LC-ESI-MS/MS) was not reported. In the present study, a new method of simultaneous determination of naringin and naringenin in human plasma was developed, and the protein binding of naringin and naringenin was investigated in the plasma of rat, dog and human by equilibrium dialysis.
MATERIALS AND METHODS
Human blood was obtained from Shenzhen Blood Center (Shenzhen, China). Rat blood was obtained from Guangdong Medical Laboratory Animal Center (Guangzhou, China). Dog blood was obtained from Guangzhou Institute of Pharmaceutical Industry (Guangzhou, China).
Naringin was purchased from National Institute for the Control of Pharmaceutical and Biological products (Beijing, China). Naringenin, isoquercitrin (internal standard, IS) and formic acid (LC grade, 50% in H2O) were purchased from Sigma (St. Louis, Mo, USA). Methanol, ethyl acetate and isopropyl alcohol were of HPLC grade from SK chemicals (Ulsan, Korea). High-purity water was prepared from Millipore-Q system (Millipore, Bedford, MA, USA). The phosphate buffer and isotone buffer were prepared as previous reported (Eriksson et al., 2005) .
Preparation of standard solutions
The individual stock standard was prepared in methanol-H2O (50:50, v/v) at a concentration of 1.0 mg/ml. The daily working standard solutions were obtained by diluting the stock solution with water at 0.02, 0.05, 0.1, 0.5, 1.0, 5.0, 10.0 μg/ml for both naringin and naringenin. The solutions for protein binding experiment were prepared by diluting the stock solution with water to 1.0, 5.0, 10.0, 50.0 μg/ml for naringin and 1.0, 5.0, 25.0, 100.0 μg/ml for naringenin. All solutions prepared were stored at 4°C.
Bioanalytical methods
Naringin and naringenin were quantified by the Agilent 1200 Series LC system (RRLC, Agilent Technol., Santa Clara, CA, USA) equipped with a binary pump, an on-line degasser, an autosampler, a thermostatically controlled column compartment and an Agilent 6410 triple quadrupole mass spectrometer equipped with an electrospray ionization interface (ESI). Separation was performed on a rapid resolution high throughput C18 column from Agilent Liu et al. 935 (ZORBAX Eclipse Plus C18: 2.1  100 mm, 1.8 μm). The mobile phase was methanol-0.25% (v/v) formic acid (52:48, v/v), and the flow-rate was 0.2 ml/min. The column temperature was maintained at 40°C. The injection volume was 10 μl. The MS conditions were set as follows: Drying gas (N2) 9.0 L/min, Neb pressure 30 psi, Capillary Voltage 4000 V, and Gas Temperature 350°C. For the analysis, the chromatograms were acquired using mass spectrometer in MRM mode, selecting the 579.2/271.0, 271.0/151.0 and 463.0/299.9 m/z ion transitions for naringin, naringenin and IS, respectively. Data were acquired and analyzed by Agilent Masshunter Workstation software Version B.01.04. An aliquot of 100 μl human plasma mixed with 20 ng of IS was transferred into a fresh 1.5 ml eppendorf tube, followed by addition of 6 μl of 5% formic acid (v/v). After 1000 μl ethyl acetate-isopropanol (19:1, v/v) was added to the tube, the sample was vortexed for 3 min, and centrifuged at 10000  g for 10 min. The supernatant was then transferred to a fresh tube and evaporated at 40°C, and the residue was dissolved in 100 μl mobile phase with vortex-mixing for 3 min, centrifuged at 13000  g for 10 min. Finally, 10 μl of the supernatant was injected into the LC-MS/MS system. The method for phosphate buffer sample preparation was the same as that of human plasma sample preparation. The method of rat and dog sample preparation was directly obtained according to previously published procedures (Liu et al., 2011; .
Plasma protein binding experiment
Separation of plasma protein bound and free naringin / naringenin were performed by equilibrium dialysis. The blood was centrifuged at 3000  g for 10 min at 4°C and the plasma was collected and stored on ice until use. Prior to use, the tubular semi permeable membranes (molecular weight cut-off 12 to 14 kDa) were soaked for 12 h in isotone buffer and therefore rinsed twice with fresh phosphate buffer. The dialysis bags were made by about ten millimeters tubular semi permeable membranes with end ligatured by cotton thread. Two milliliters plasma containing naringin (100, 500, 1000, 5000 ng/ml) or naringenin (100, 500, 2500, 10000 ng/ml) was removed into the dialysis bag, and then placed into wide-mouth bottle containing 20 ml phosphate buffer. The dialysis bag was adjusted to suspend in phosphate buffer and the inside and outside liquid surface kept in the same level. After centrifugation was performed at 37°C on the rotary shaker with 90 rpm, the time to reach equilibrium was tested by collecting samples from both buffer and plasma at 2, 4, 6, 8, 12 and 24 h. Plasma protein binding of naringin and naringenin was assessed after incubation at 37°C within equilibrium time achieved. Plasma and phosphate buffer samples were collected, and assayed by LC-ESI-MS/MS system.
RESULTS AND DISCUSSION

Method validation
The assay of naringin and naringenin in human plasma and phosphate buffer was validated for selectivity, linearity, precision, accuracy, matrix effect, extract recovery and stability according to the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) guidelines (ICH Expert Working Group, 2005) . The methods for the simultaneous quantification of naringin and naringenin in rat and dog plasma have been validated in previous studies (Liu et al., 2011; . The selectivity was evaluated by comparing the chromatograms of blank buffer / human plasma with those of corresponding standard in buffer / plasma sample spiked with naringin, naringenin and IS. No interfering peaks were observed. The retention times were 1.9, 2.2 and 4.4 min for naringin, IS and naringenin, respectively. The linearity of the calibration curve was obtained by plotting the peak-area ratios of naringin / naringenin to IS versus the concentration of naringin / naringenin with 1/x 2 weighted least-squares linear regression analysis over the concentration range for both naringin and naringenin in buffer / plasma sample. The good linear relationships were obtained with correlation coefficients >0.99 presented in Table 1 . The lower limit of quantification (LLOQ) in 100 μl buffer and plasma sample for all analytes can be reliably quantified with precision <11% and accuracy between -6.2 and 11.8% for ten replicates. The intra-and inter-day (3 days) precision were assessed by analyzing five replicates at three different concentration levels and the results summarized in Table  2 . All values were found within recommended limits, which indicated that the analytical method was accurate.
The matrix effect was examined by comparing peak areas of each analyte from the spike-after-extraction samples at three different levels to the neat standards at the same concentrations. Thus ion suppression or ion enhancement from matrix was negligible for this method. The matrix effect for naringin and naringenin was in the range of 71 to 83% (n=5) as shown in Table 2 . The extract recovery of naringin and naringenin were calculated by comparing the mean peak areas of analytes spiked before extraction divided by the areas of analytes of samples spiked after extraction and multiplied by 100, and the results are summarized in Table 2 .
The stabilities of naringin and naringenin in buffer and plasma were assessment including solution stability in autosampler for 24 h, after going through three freeze and thaw cycles, after long-term (-70°C for 1 month) and short-term (room temperature for 48 h). There was no significant degradation of naringin and naringenin found (Table 3) , and they were stable with acceptable criteria.
Protein binding
The time course to equilibrium of naringin and naringenin was examined with the plasma of human. The total naringin concentration in the plasma was 467.3 ± 21.0 mg/ml (n=3) before incubation, and gradually decreased to 180.3 ± 11.5 and 133.2 ± 7.6 ng/ml at 2 and 4 h after incubation, respectively. At 6 h after incubation or later, there were no significant changes in the naringin concentration in the plasma sample, ranging from 124.5 ± 8.2 to 133.6 ± 2.1 ng/ml. In contrast, the naringin in the buffer samples gradually increased to 32.3 ± 1.2 ng/ml at 4 h, and no significant changes was found at 6 h after incubation or later, ranging from 32.4 ± 1.4 to 35.6 ± 0.7 ng/ml. The procedure for naringenin also took 6 h incubation to reach equilibrium (Figure 1 ). This finding agreed with naringin and naringenin obtained in the case of the plasma of rat and dog (data not shown). Base on the aforementioned findings, we set the incubation time of 12 h for the equilibrium dialysis method.
The concentration of naringin and naringenin in phosphate buffer [concentration of unbound drug (C u )] and in plasma [concentration of bound drug (C t )] were determined by RRLC-ESI-MS/MS at 12 h after incubation, and the protein-binding ratio (B) was calculated by B (%) = [(C t -C u ) / C t ] × 100. As shown in Figure 2A , saturation of the plasma protein binding of naringin was not observed at concentrations ranging from 100 to 5000 ng/ml. The amount of bound naringin in the plasma increased linearly with the concentration in test species. The plasma protein binding ratios of naringin were from 83.30 to 84.56%, 72.14 to 74.06% and 48.17 to 51.33% in rat, human and dog plasma, respectively, and no concentration dependence were evident across the entire concentration range ( Figure 2B ). The plasma protein binding of naringin was high in rat plasma, moderate in human plasma and low in dog plasma.
No saturation of the bound naringenin was found in the concentration range in rat, dog and human plasma ( Figure 3A ). All binding ratios for naringenin exceed 94% over all concentration studied, implying that naringenin performed high protein plasma rates in three test species (human > rat > dog, Figure 3B ). The protein bonding ratio in human plasma was closed to 100% at 100 ng/ml, and steady at approximate 97% at the naringenin concentrations ranging from 500 to 10000 ng/ml. These findings were also seen in a protein binding study of Catechin and taxifolin in human plasma (Kurlbaum and Högger, 2011) . The high protein binding ratios indicated Table 2 . Intra-and inter-day precision, matrix effect and extract recovery of naringin and naringenin in human plasma and phosphate buffer (n = 5). that naringenin exists mainly in the bound form in the circulating blood of rat, dog and human at a wide range of naringenin concentrations. The differences of protein binding between naringin and naringenin indicated that the 7-O-rhamnoglucoside of naringin was the most important factor in the process protein binding.
Sample matrix
Previous research reported that the binding constant of naringenin to human serum albumin was 7.7 × 10 4 M -1 (Khan et al., 2011) , which was more than 4 times than that of naringin (Zhang et al., 2008) . However, serum albumin, only a part of plasma protein, could not reflect the whole complicated plasma protein. In these results, less than 2 times protein binding ratios of naringin compared with that of naringenin were obtained, indicating other protein in plasma played a very important part in the plasma protein binding of naringin and naringenin.
The transport of drugs in the circulatory system is an important step in the overall process of delivery. Several studies showed that plasma protein binding could enhance drug stability and half-life (Manach et al., 2005) . Investigating interactions between naringin / naringenin and plasma protein can provide a pertinent insight into the fate of circulating them in terms of excretion rate or delivery to tissues. For instance, following administration of pure naringin, the mean residence time (MRT) of naringin was 6.48 h in rat (Fang et al., 2006 ) and 3.3 h in dog (Mata-Bilbao et al., 2007) , and after oral administration of naringenin, the mean elimination half-life of naringenin was 2.89 h for rat and 2.31 h for human (Kanaze et al., 2007) . Interesting, this ranking parallels the protein binding ratio of naringin and naringenin in different species plasma. The findings in this study were helpful to understand the pharmacokinetic and disposition of naringin and naringenin.
Conclusion
Natural products have been considered as an invaluable source for the drug discovery process. Naringin and naringenin are two natural products with many biological and pharmacological activities. As knowledge about active principlesprotein interaction contribute to insights into pharmacokinetic and pharmacodynamic properties, we successfully elucidated the protein binding of naringin and naringenin in rat, dog, and human plasma using equilibrium dialysis and LC-ESI-MS/MS method in this study. The results demonstrated species differences in the protein binding of naringin and its aglycone. The protein binding ratios of naringin was high in rat plasma, moderate in human plasma and low in dog plasma. However, naringenin revealed highest plasma protein binding over 94%. The results provided new data as a basis for more comprehensive understanding of the pharmacokinetics and pharmacodynamics of naringin and naringenin. 
